George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Showing as +37% when it....isn't? Hardly ever seems to be accurate for this share.
Feedback ‘how likely am I going to recommend N4p to another investor’ well Nigel once you realise the objective of a business is to make money and not just a 20 year loss making concept that keeps asking the market for more money, then I might just say this is more than just a very long trial going nowhere. Nowhereman please listen , seems obvious what your missing. All it is at the moment is university projects. One day Rodney……
Maybe not a blockbuster rns but i see this as a good start for the Nanogenics work. Anyone who took the time to read the inital Nanogenics rns and the 2nd October presentation would not have realistically expected much more at this stage.
It could also be that investors are wary, Dan55. I was invested in Oxford Pharmascience, which Nigel was CEO of. All I have seen with N4P is a repeat of exactly what happened during his tenure at Oxford Pharmascience. Lots of hype but a gradual decline in the share price. N4P has gone from over 25p in June 2018 to sub 1 p today at 0.92p. I hope NT delivers this time around as Nanogenics and Nuvec have promise. Maybe just maybe this time around NT is going to be successful? He is going to have to deliver a collaboration soon though.
Look at the share price Homer until the cash flow is sort it’s going no where. Need a partner or we will see another placing coming . Same pattern last 3-4 years.
Why would they need to raise? It was already confirmed in the investor's call that they would not need to.
They would look at other avenues.
Also, the last placement has not even been finished being sold in the market. Hence the large trades.
But a lot of people who invest don't even listen to the presentations.
I want them to get it out the way.
Running low on funds that’s why share price is down . Doesn’t matter what N4p says , at some point soon will get the begging bowl out.
IVE BEEN WAITING 10 YEARS
It's not huge news Kris! Otherwise, the SP would be moving up and not down.
A £3m market cap company with this potential represents very positive risk/reward.
It’s frustratingly underwhelming. However when the preclinical saga ends (with a good result) and we’ve got products ready to be licensed out, or takeover. The wait will be worth it…. Fingers crossed.
I have to agree with the first posters. As a long term holder I am underwhelmed.
Exactly. Big news in our space. We now have Nanogenics as well as Nuvec at the cutting edge, both with huge potential.
* More than 75 million people worldwide are affected by Glaucoma
* The total Glaucoma treatment market size in 2021 exceeded $5.5 billion and is growing.
CEO: " A novel product in this space alone represents a good opportunity for Nanogenics and importantly the antifibrotic siRNA sequence can also be used to investigate other fibrotic treatments for liver and lung fibrosis."
Good luck, Brighty
A de-ramp. Quelle surprisé.
This is huge news!
Just a puff on a dog end?
Very exciting but no cigar
Odd how this site has N4P up 10% on Friday, whilst Google has it down 10%? Same price tho, 1.10.
A break above red line will indicate a break of structure ,anticipate it to 1.50 range
https://invst.ly/12-3sf
Dcraig i would not pay much attention to that. Investors in companies like N4 do not need the product to get to market to make money. Companies with products years away from market at clinical trial stage are often valued significantly higher than we are now.
The question for investors is whether N4's potential newsflow from Nuvec & Nanogenics can take it to a much higher level than we see today.
It’s a totally irrelevant article, the patents are continually updated as the product changes its manufacturing or loading process. Classic example is the dispersion results, the company had to alter the process and that means also ensuring that new procedure is protected through all areas.
Remember one thing, the business model is about pre clinical revenue as much as it is about royalties. The value for N4 and its shareholders is a paying collaborative partnerships, which we seriously fail at.
That guy from the Dhaka Tribune which is everybody's first stop for investor advice is talking nonsense. It will be far quicker than that.
Sorry if this is old but i came across this article that was posted shortly after the us patent was granted. They state that at the stage of development we are currently in we won't see a commercially viable product for around a decade if at all.
Does anyone have any thoughts on this?
https://www.dhakatribune.com/financial-markets/321006/n4-pharma-lon-n4p-up-33%25-on-patent-this-isn%E2%80%99t
Held better than I expected to be fair, hoping the last placement holders are long gone.
We’ve all been here years, been shown the dangling carrot numerous times and unfortunately things haven’t always gone as expected, running experiments with as little expense as possible isn’t the way big business does things but hey, we’re doing the best we can without trying to dilute every few months.
Still have hopes for Nuvec, I’m confident it’s makeup and ease of production will ultimately fall into the hands of a company that want a lipid alternative.
Bottom drawer holding for now.
Price held 1.15 all day DCraig